FDA approves Mirum’s LIVMARLI for cholestatic pruritus

14 Mar 2024
·
Deals
www.pharmaceutical-technology.com
Drug ApprovalOrphan DrugClinical ResultPhase 3Acquisition
Mirum Pharmaceuticals’s LIVMARLI (maralixibat) oral solution is now available in the US for cholestatic pruritus in patients with PFIC. Credit: Mirum Pharmaceuticals / Business Wire.
Mirum PharmaceuticalsAdministration (FDA) has approved Mirum Pharmaceuticals’s LIVMARLI (marcholestatic pruritusion to treat cholePFICic prurituMirum Pharmaceuticals
A once-daily, orally administered ileal bile acid transporter inhibitorprogressive familial intrahepatic cholestasis (PFIC)IC.
The approval is based on findings ileal bile acid transporterinical trialLIVMARLIFIC patients.PFIC
The randomised trial enrolled people with PFIC genetic types PFIC1, PFIC2, PFIC3, PFIC4 and PFIC6, along with people with unidentified mutational status.
Terns scores FDA orphan designation for CML therapy
FDA issues CRFDAo Mapi Pharma for GA DepCMLto treat RMS
The FDA, the European Commission and Health Canada have also granted approval for LIVMARLI for the treatment of cholestatic pruritus in patients with Alagille syndrome in their respective regions.
FDAaddition to itsMapi Pharmaprovals, Mirum has fileRMS supplemental new drug application to the FDA. The aim is to introduce a higher concentration formulation of LIVMARLI, which was utilised in the Phase III MARCH study.
This could expand the treatment’s label for younger PFIC patients later in 2024.
A raFDAgenetic disorder, PFIC resultsHealth Canadave liver disease that can go on LIVMARLI liver failure.cholestatic pruritusAlagille syndromeAlagille syndrome
Mirum Pharmaceuticals CEO Chris Peetz Mirumd: “LIVMARLI has the potential to have a transformatioFDA impact for patients with cholestatic pruritus associated with PLIVMARLI importantly, offers an option for those patients with the rarest of subtypes.
“Thank you to the patients, families and clinicians whose study participation made this approval possible.”
In September 2023, the coPFICy concluded progressive liver diseasele acid product portfolioliver failureherapeutics.
Mirum Pharmaceuticalsts and assets related to CLIVMARLIcholic acid) and Chenodal (chenodiol).cholestatic pruritusPFIC
Travere secured $210m from Mirum, with the potential to receive $235m in sales-based milestone payments.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.